Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

Ocugen OCGN reported a second-quarter 2026 loss of 7 cents per share, which was wider than the Zacks Consensus Estimate as well as the year-ago loss of 5 cents. Higher research and development spending weighed on results.

Revenues rose 8.4% year over year to $1.5 million and slightly beat the Zacks Consensus Estimate of $1.4 million. The company’s top line currently comprises only collaboration revenues.

OCGN’s Costs Climb as Pipeline Spending Advances

Total operating expenses increased 18.2% year over year to $17.9 million. Research and development expenses rose 27.2% to $10.7 million, while general and administrative expenses increased 7.0% to $7.2 million.

Cash, cash equivalents and restricted cash totaled $100.4 million as of June 30, 2026, up from $32.2 million as of March 31. The increase followed the closing of $130.0 million of 6.75% convertible senior notes due 2034, which generated about $112.5 million in net proceeds.

Ocugen used about $32.7 million of those proceeds to fully retire its Avenue Capital loan and eliminate 12.25% interest-rate debt. Management expects the financing to extend the cash runway into 2028, supporting the company’s late-stage clinical programs and planned regulatory submissions.

Ocugen’s shares declined 3% on Wednesday after the results were announced. Year to date, shares of OCGN have declined 8.2% compared with the industry’s 3.5% decline.

Image Source: Zacks Investment Research

OCGN’s Pipeline Progress & Clinical Updates

Ocugen is advancing its ophthalmology gene therapy pipeline, targeting three biologics license application (BLA) submissions by 2028. The first half of 2027 is expected to be catalyst-rich, with late-stage top-line data anticipated for OCU400 and OCU410ST.

Enrollment has been completed in a phase III liMeliGhT study on lead modifier gene therapy candidate, OCU400, to treat Retinitis pigmentosa, or RP, a rare genetic disorder that can lead to vision loss and blindness. Top-line data from the phase III study is expected in the first quarter of 2027. Management said the FDA feedback keeps the rolling BLA pathway tied to the top-line data, with completion of the filing targeted for the second quarter of 2027 and potential approval in the fourth quarter as a treatment option for early- to late-stage RP.

OCU410ST is being developed as a one-time gene therapy for the treatment of Stargardt disease, a rare inherited retinal disorder. In April 2026, the company completed enrollment and dosing in the phase II/III GARDian3 pivotal confirmatory study on OCU410ST for Stargardt disease. Management expects an interim outcome decision for the first 50% of subjects at eight months in the third quarter of 2026. Top-line data are anticipated in the second quarter of 2027, with a BLA submission planned for mid-2027.

The FDA cleared the phase III ArMaDa3 registrational study of Ocugen’s another important candidate, OCU410, for geographic atrophy, an advanced stage of dry age-related macular degeneration. Ocugen plans to initiate the global phase III study by September. The program is supported by positive 12-month phase II data showing a statistically significant 31% reduction in geographic atrophy lesion growth at the optimal dose in the target lesion-size population. BLA and Marketing Authorization Application filings are targeted for 2028.

OCGN's Zacks Rank & Stocks to Consider

Ocugen currently carries a Zacks Rank #3 (Hold).

Ocugen, Inc. Price and Consensus

Ocugen, Inc. price-consensus-chart | Ocugen, Inc. Quote

Some better-ranked stocks in the biotech sector are Repligen RGEN, Harmony Biosciences HRMY and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 2.7% year to date.

Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.

Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.33. Over the same period, EPS estimates for 2027 have surged from $3.64 to $3.92. HRMY shares are up 3.6% year to date.

Harmony Biosciences’ earnings missed estimates in three of the trailing four quarters, while beating in just one, with the average negative surprise being 13.97%.

Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 159.3% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research